New study aims to spare women from chemo and major surgery for common breast cancer
NCT ID NCT07428018
First seen Feb 24, 2026 · Last updated Apr 28, 2026 · Updated 7 times
Summary
This study tests whether a genetic test (Oncotype DX) can help decide if women with a common type of early breast cancer (HR+/HER2-) can skip chemotherapy and instead receive a targeted drug (abemaciclib) plus hormone therapy before surgery. The goal is to see if this approach allows more women to have breast-conserving surgery instead of mastectomy and avoid removing many lymph nodes. About 150 women will participate in this phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Istituto di Ricerche Farmacologiche Mario Negri IRCCS
Milan, MI, 20156, Italy
Conditions
Explore the condition pages connected to this study.